精准免疫治疗改善脓毒症结局:ImmunoSep随机临床试验
ImmunoSep是一项在6个国家开展的双盲、双模拟、安慰剂对照随机临床试验,纳入符合Sepsis-3定义且为社区获得性或医院获得性肺炎、呼吸机相关性肺炎或菌血症合并脓毒症的患者,按生物标志物分为巨噬细胞活化样综合征(血铁蛋白>4420 ng/mL)或脓毒症诱导的免疫麻痹(血铁蛋白≤4420 ng/mL且CD45/CD14单核细胞上人类白细胞抗原DR受体<5000)。精准免疫治疗组分别接受阿那白滞素静脉注射或重组人干扰素γ皮下注射,疗程最长15天。主要终点第9天SOFA评分较基线下降至少1.4分的达成率,精准免疫治疗组为35.1%(46/131),安慰剂组为17.9%(26/145),差异17.2%(95%CI 6.8%至27.2%;P=0.002);28天死亡率两组无统计学显著差异。
要点
- 精准免疫治疗组第9天SOFA评分下降≥1.4分的达成率为35.1%(46/131),安慰剂组为17.9%(26/145),差异17.2%(95%CI 6.8%至27.2%;P=0.002)。
- 28天死亡率在精准免疫治疗组与安慰剂组之间无统计学显著差异。
- 共报告1069例严重治疗中出现的不良事件(88.8%);阿那白滞素组贫血发生率增加,重组人干扰素γ组出血发生率增加。
- 入组条件为Sepsis-3定义的脓毒症,且为社区获得性或医院获得性肺炎、呼吸机相关性肺炎或菌血症合并脓毒症,并符合巨噬细胞活化样综合征(血铁蛋白>4420 ng/mL)或脓毒症诱导的免疫麻痹(血铁蛋白≤4420 ng/mL且CD45/CD14单核细胞上人类白细胞抗原DR受体<5000)。
适用人群与场景
- 符合Sepsis-3定义的脓毒症患者,且为社区获得性或医院获得性肺炎、呼吸机相关性肺炎或菌血症合并脓毒症。
- 按生物标志物分为:巨噬细胞活化样综合征(血铁蛋白>4420 ng/mL)或脓毒症诱导的免疫麻痹(血铁蛋白≤4420 ng/mL且CD45/CD14单核细胞上人类白细胞抗原DR受体<5000)。
诊断标准与关键阈值
- 巨噬细胞活化样综合征:血铁蛋白>4420 ng/mL。
- 脓毒症诱导的免疫麻痹:血铁蛋白≤4420 ng/mL且CD45/CD14单核细胞上人类白细胞抗原DR受体<5000。
- 主要终点:第9天平均SOFA评分较基线下降至少1.4分;SOFA评分评估6个器官系统,每项0分(无功能障碍)至4分(衰竭),总分0分(正常)至24分(最严重多器官衰竭)。
处置流程与药物剂量
- 精准免疫治疗组中,巨噬细胞活化样综合征患者接受阿那白滞素静脉注射和安慰剂皮下注射。
- 精准免疫治疗组中,脓毒症诱导的免疫麻痹患者接受重组人干扰素γ皮下注射和安慰剂静脉注射。
- 安慰剂组接受静脉和皮下安慰剂。
- 治疗最长持续15天。
研究设计与关键结果
- 研究类型:随机、双盲、双模拟、安慰剂对照临床试验,在6个国家开展;筛查672例,随机281例,主要分析人群276例(平均[SD]年龄70[13]岁;女性93例[33.7%];基线SOFA评分中位数9[IQR 7-11])。
- 主要终点:精准免疫治疗组46/131例(35.1%)达成SOFA下降终点,安慰剂组26/145例(17.9%)达成,差异17.2%(95%CI 6.8%至27.2%;P=0.002)。
- 关键次要终点:28天死亡率两组无统计学显著差异。
- 不良事件:共报告1069例严重治疗中出现的不良事件(88.8%);阿那白滞素组贫血发生率增加;重组人干扰素γ组出血发生率增加。
证据类型、等级与局限
- 证据类型:随机双盲双模拟安慰剂对照临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在脓毒症患者中,针对巨噬细胞活化样综合征和脓毒症诱导的免疫麻痹的精准免疫治疗,与安慰剂相比改善了第9天器官功能障碍。
- 精准免疫治疗需依据血铁蛋白>4420 ng/mL或血铁蛋白≤4420 ng/mL且CD45/CD14单核细胞上人类白细胞抗原DR受体<5000进行分层,分别选用阿那白滞素静脉注射或重组人干扰素γ皮下注射,疗程最长15天。
- 阿那白滞素组贫血发生率增加,重组人干扰素γ组出血发生率增加。
指南或共识出处
- ImmunoSep随机临床试验(ClinicalTrials.gov标识符:NCT04990232)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Sepsis is heterogeneous, and the optimal strategy for tailoring immunotherapy is uncertain.
OBJECTIVE: To investigate whether precision immunotherapy guided by the presence of macrophage activation-like syndrome or sepsis-induced immunoparalysis improves organ dysfunction by day 9.
DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, double-dummy, placebo-controlled clinical trial conducted in 6 countries. Patients with sepsis, defined by Sepsis-3, were included if they had community-acquired or hospital-acquired pneumonia or ventilator-associated pneumonia or bacteremia and sepsis and had displayed either macrophage activation-like syndrome (blood ferritin >4420 ng/mL) or sepsis-induced immunoparalysis (blood ferritin ≤4420 ng/mL and <5000 human leukocyte antigen DR receptors on CD45/CD14 monocytes). The first patient was enrolled August 5, 2021, and the last follow-up, April 29, 2024.
INTERVENTIONS: Eligible patients were randomized to receive standard care and precision immunotherapy or standard care and placebo. Those in the precision immunotherapy group with macrophage activation-like syndrome received anakinra intravenously (IV) and placebo subcutaneously, and those with sepsis-induced immunoparalysis received subcutaneous recombinant human interferon gamma and IV placebo. Those in the placebo group received both IV and subcutaneous placebo. Treatment was administered for up to 15 days.
MAIN OUTCOMES AND MEASURES: The primary end point was a decrease of at least 1.4 points in the mean Sequential Organ Failure Assessment (SOFA) score from baseline by day 9. The SOFA score evaluates 6 organ systems, ranging from 0, no dysfunction, to 4, failure, and the total score ranges from 0, normal, to 24, most severe form of multiorgan failure. Key secondary outcomes included 28-day mortality.
RESULTS: Of 672 patients assessed for eligibility, 281 were randomized and 276 were included in the primary analysis population (mean [SD] age, 70 [13] years; 93 females [33.7%]; median baseline SOFA score, 9 [IQR, 7-11]). The SOFA decrease end point was attained by 46 of 131 patients (35.1%) in the precision immunotherapy group and by 26 of 145 patients (17.9%) in the placebo group (difference, 17.2% [95% CI, 6.8% to 27.2%]; P = .002). Mortality at 28 days was not statistically significantly different between groups. A total of 1069 serious treatment-emergent adverse events (88.8%) were reported; increased incidence of anemia was noted in the anakinra group; and hemorrhage in the recombinant human interferon gamma group.
CONCLUSIONS AND RELEVANCE: Among patients with sepsis, precision immunotherapy targeting macrophage activation-like syndrome and sepsis-induced immunoparalysis improved organ dysfunction by day 9 compared with placebo.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04990232.
参考来源
- Giamarellos-Bourboulis EJ, Kotsaki A, Kotsamidi I, et al. Precision Immunotherapy to Improve Sepsis Outcomes: The ImmunoSep Randomized Clinical Trial. JAMA. 2026. PMID: 41359996. doi:10.1001/jama.2025.24175
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。